Metabolic medicines

Danuglipron

An oral GLP-1 research medicine whose development was discontinued after a potential liver-injury signal.

Phase 2 weight findings; development discontinued

Danuglipron molecular structure — Structure reference · C31H30FN5O4

Practical use

Reviewed practical notes

Include retention: Check how many people stayed on treatment, not just the average weight change.
Date the evidence: An article publication date can be later than the decision to end development.
Separate versions: Twice-daily trial results and once-daily optimization data belong to different study settings.

Published phase 2b trial

Pfizer April 2025 discontinuation announcement

Overview

Danuglipron is a small-molecule GLP-1 receptor agonist investigated as an oral obesity treatment. Weight loss in a development trial is only one part of the evidence: tolerability, retention and subsequent safety findings can change the value of a program.

Risks and limitations

Pfizer stopped development in April 2025 after reviewing the overall data, including a participant with potential drug-induced liver injury in a formulation-optimization study. The company said the person was asymptomatic and the finding resolved after treatment stopped.

How to read this

A later publication of earlier trial data does not mean the program restarted. The stopped-development status and the high discontinuation rate belong alongside any weight-loss result.

Research explained

Phase 2b obesity study

Who was studied

628 adults randomized; 626 treated, without diabetes, in a study lasting 26 or 32 weeks depending on the cohort.

What was found

Weight loss favored danuglipron, but only 39.3% completed treatment. About 38% discontinued because of adverse events, most commonly gastrointestinal problems.

What it cannot establish

Substantial attrition complicates interpretation and real-world tolerability. Results from the studied formulation cannot settle safety of another formulation or override a later development decision.

Read the original study

Why the program status changes the interpretation

The sponsor announcement describes discontinuation after a review of safety, efficacy and regulatory feedback. A potential liver injury is not a measured incidence for all users, but it is material information that a benefit-only summary would omit.

Supporting source

Sources